# Wei Cheng

> Wei Cheng is a Series B investor at TF Capital (Boston) backing Medical and Therapeutics. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [TF Capital](https://shizune.co/investors/profile/tf-capital)
- Location: Boston, United States
- Total investments: 1
- Last investment: Mar 2023
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/wei-cheng-04631377/?trk=pub-pbmap

Wei Cheng is a managing director of TF Capita.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Therapeutics | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Allorion Therapeutics | Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses. Allorion operates two locations in Natick, Massachusetts, and Guangzhou, China. | $50M | Series B | Mar 09, 2023 |  |

1 of 1 investments shown.

## Co-investors
- [INCE Capital](https://shizune.co/investors/profile/ince-capital) — VC Fund, 2 deals together
- [3SBio Inc.](https://shizune.co/investors/profile/3sbio) — VC Fund, 1 deal together
- [Elikon Venture](https://shizune.co/investors/profile/elikon-venture) — VC Fund, 1 deal together
- [LongRiver Investments](https://shizune.co/investors/profile/long-river-investments) — VC Fund, 1 deal together
- [Octagon Capital Advisors](https://shizune.co/investors/profile/octagon-capital-advisors) — VC Fund, 1 deal together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 1 deal together

## About TF Capital

VC Fund · Pudong, China

TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.

4 contacts available at TF Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dr. Zhang Yibo | Partner | https://shizune.co/investors/profile/dr-zhang-yibo |
| H.J. Jiang | Founder & CEO | https://shizune.co/investors/profile/kevin-chiang-fda9 |
| Wei Cheng | Managing Director | https://shizune.co/investors/profile/wei-cheng-2639 |
| Yi Liu | Director | https://shizune.co/investors/profile/yi-liu-0a01 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Wei Cheng invest in?

Wei Cheng invests primarily in Medical, Therapeutics and Pharmaceutical startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Wei Cheng last invest?

The most recent investment recorded for Wei Cheng closed in Mar 2023. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co